-
- Position
- PROFESSOR | Medicine, General Internal Medicine
-
- Language
- English
-
- Hospital Affiliation
- The Mount Sinai Hospital
He received a K award from the Agency for Healthcare Research and Quality (AHRQ) to identify determinants of medication adherence and outcomes among inner-city asthmatics and a grant funded by the New York State Department of Health to assess the management of minority asthmatics. He has also been involved in several inpatient, outpatient and physician studies assessing the treatment and outcomes of inner-city asthmatics. He is also the PI of an R01 grant evaluating self-management of patients with chronic obstructive pulmonary disease. He was the PI of an R03 grant to validate a pulmonary tuberculosis prediction rule.
News
Mount Sinai Study Shows that Language Barriers may Interfere with the Care of Asthma Patients.
Find out more here
Dr. Juan Wisnivesky discusses lung cancer risks in The Daily News feature The Daily Check Up.
Multi-Disciplinary Training Areas
Clinical Research Education Program [CLR], Public Health [PH]
Education
MD, University of Buenos Aires, Argentina
MPH, Columbia University
DrPH, Columbia University
Language
English
2010
Research Excellence Award
Department of Medicine, MSSM
2009
Joseph L. Fleiss Prize Biostatistics , Columbia University
1998
Young Investigator Award
CHEST
1998
J. Burns Amberson Fellow
American Lung Association of New York
1996
Outstanding House Officer Award
Montefiore Medical Center, Albert Einstein College of Medicine
1990
Cum Laude
University of Buenos Aires School of Medicine
Research interests include:
Asthma, lung cancer screening, Tuberculosis. Please visit the Wisnivesky Laboratory.
Clinical Trials
Determinants fo Undertreatment Amoung Patients with Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a leading cause of death in the United States and represents a major health, social, and economic burden. Despite strong evidence regarding the benefits of pharmacologic treatment on symptoms, quality of life, morbidity, and mortali...
Wisnivesky JP, Halm EA. Sex differences in lung cancer survival: do tumors behave differently in elderly women?. J Clin Oncol 2007; 25(13): 1705-1712.
Wisnivesky JP, Henschke C, Yankelevitz D. Diagnostic percutaneous transthoracic needle biopsy does not affect survival of stage I lung cancer. Am J Respir Crit Care Med 2006; 174(6): 684-688.
Wisnivesky JP, McGinn T, Henschke C, Hebert P, Iannuzzi M, Halm E. Ethnic disparities in the treatment of stage I non-small cell lung cancer. Am J Respir Crit Care Med 2005; 171: 1158-1163.
Wisnivesky JP, Kaplan J, McGinn T, Henscke C, Crystal RG. Evaluation of clinical parameters to predict positive culture for Mycobacterium Tuberculosis in inpatients. Arch Int Med 2000; 160: 2471-2476.
Wisnivesky JP, Kattan M, Evans D, Leventhal H, Musumeci-Szabó TJ, McGinn T, Halm EA. Assessing the relationship between language proficiency and asthma morbidity among inner-city asthmatics. Medical care 2009 Feb; 47(2).
Wisnivesky JP, Henschke CI, Swanson S, Yankelevitz DF, Zulueta J, Marcus S, Halm EA. Limited resection for the treatment of patients with stage IA lung cancer. Annals of surgery 2010 Mar; 251(3).
Wisnivesky JP, Halm E, Bonomi M, Powell C, Bagiella E. Effectiveness of radiation therapy for elderly patients with unresected stage I and II non-small cell lung cancer. American journal of respiratory and critical care medicine 2010 Feb; 181(3).
Wisnivesky JP, Arciniega J, Mhango G, Mandeli J, Halm EA. Lymph node ratio as a prognostic factor in elderly patients with pathological N1 non-small cell lung cancer. Thorax 2011 Apr; 66(4).
Wisnivesky JP, Smith CB, Packer S, Strauss GM, Lurslurchachai L, Federman A, Halm EA. Effectiveness and Toxicity of Adjuvant Chemotherapy in Elderly Patients with Resected Stage II and IIIA Lung Cancer: Observational Cohort Analysis. BMJ 2011; 343.
Wisnivesky JP, Teitelbaum S, Todd AC, Boffetta P, Crane M, Crowley L, de la Hoz R, Dellenbaugh C, Harrison D, Herbert R, Kim H, Jeon Y, Kaplan J, Katz C, Levin S, Luft B, Markowitz B, Moline JM, Ozbay F, Pietrzak RH, Shapiro M, Sharma V, Skloot G, Southwick S, Stevenson LA, Udasin I, Wallensteiin S, Landrigan PJ. Persistence of multiple illnesses in World Trade Center rescue and recovery workers: a cohort study. Lancet 2011 September; 378: 888-97.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Wisnivesky during 2016 and/or 2017. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- AstraZeneca
- Quintiles
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.